Lybalvi 5-10 MG tablet UU 30S
Ended Awarded Last action
- Contract number
- SPE2DR26F5X17
- Awardee
-
Amerisourcebergen Drug Corp UEI KABZK8W6PQT3 Part of Cencora, Inc.
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $16,804
Award facts
- Contract value 100% obligated
- $16,804.23 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Conshohocken, PA 19428, USA
Award details come from SAM.gov/FPDS.
About this award
Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc., was awarded a delivery order valued at $16.8K on January 12, 2026, for the supply of LYBALVI 5-10 mg tablets (30-count units) to support federal medical procurement needs. The award is a firm fixed-price delivery order with an ultimate completion date of January 13, 2026, and represents a non-set-aside competitive award. The place of performance is Conshohocken, Pennsylvania, where Amerisourcebergen maintains its corporate headquarters. This delivery order is issued under Amerisourcebergen's larger Indefinite Delivery Contract with the Defense Logistics Agency (DLA) Troop Support Medical, designated SPE2DX and valued at $999,999,999.00 through December 2026, which serves as a comprehensive global pharmaceutical support vehicle for military healthcare programs worldwide.
The Defense Logistics Agency, which funds this award as part of the Department of Defense's medical supply chain operations, utilizes such delivery orders to procure essential pharmaceutical products across multiple therapeutic domains to support military treatment facilities and veteran healthcare programs. Amerisourcebergen's parent company, Cencora, Inc., holds a complementary IDC with DLA valued at up to $999,999,999.00 through December 31, 2031, underscoring the company's significant role as a primary pharmaceutical distributor for federal military and healthcare operations. LYBALVI (lurasidone) is an atypical antipsychotic medication used in the treatment of schizophrenia and bipolar disorder, reflecting the breadth of psychiatric and neurological medications supplied through this contract vehicle.
Quick answers
Who was awarded contract SPE2DR26F5X17?
SPE2DR26F5X17 was awarded to Amerisourcebergen Drug Corp by Defense Logistics Agency (Department of Defense) on January 12, 2026.
How much is contract SPE2DR26F5X17 worth?
The government has obligated $16,804 on SPE2DR26F5X17.
Is contract SPE2DR26F5X17 an order under another contract?
Yes. SPE2DR26F5X17 is a delivery order under SPE2DR25D3101, an indefinite delivery contract.
Was contract SPE2DR26F5X17 competed?
The extent of competition for SPE2DR26F5X17 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award